Affiliation:
1. MRC Weatherall Institute of Molecular Medicine John Radcliffe Hospital, University of Oxford Oxford UK
2. Department of Clinical Genetics Liverpool Women's NHS Foundation Trust Liverpool, England UK
3. West Midlands Regional Clinical Genetics Service and Birmingham Health Partners Birmingham Women's and Children's Hospitals NHS Foundation Trust Birmingham UK
4. Birmingham Craniofacial Unit Birmingham Women's and Children's Hospitals NHS Foundation Trust Birmingham UK
5. Clinical Genetics Service Great Ormond Street Hospital for Children NHS Foundation Trust London UK
6. Oxford Craniofacial Unit Oxford University Hospitals NHS Foundation Trust Oxford UK
7. Oxford Centre for Genomic Medicine Oxford University Hospitals NHS Foundation Trust Oxford UK
Abstract
AbstractThe RUNT‐related transcription factor RUNX2 plays a critical role in osteoblast differentiation, and alterations to gene dosage cause distinct craniofacial anomalies. Uniquely amongst the RUNT‐related family, vertebrate RUNX2 encodes a polyglutamine/polyalanine repeat (Gln23‐Glu‐Ala17 in humans), with the length of the polyalanine component completely conserved in great apes. Surprisingly, a frequent 6‐amino acid deletion polymorphism, p.(Ala84_Ala89)del, occurs in humans (termed 11A allele), and a previous association study (Cuellar et al. Bone 137:115395;2020) reported that the 11A variant was significantly more frequent in non‐syndromic sagittal craniosynostosis (nsSag; allele frequency [AF] = 0.156; 95% confidence interval [CI] 0.126–0.189) compared to non‐syndromic metopic craniosynostosis (nsMet; AF = 0.068; 95% CI 0.045–0.098). However, the gnomAD v.2.1.1 control population used by Cuellar et al. did not display Hardy–Weinberg equilibrium, hampering interpretation. To re‐examine this association, we genotyped the RUNX2 11A polymorphism in 225 individuals with sporadic nsSag as parent–child trios and 164 singletons with sporadic nsMet, restricting our analysis to individuals of European ancestry. We compared observed allele frequencies to the non‐transmitted alleles in the parent–child trios, and to the genome sequencing data from gnomAD v.4, which display Hardy–Weinberg equilibrium. Observed AFs (and 95% CI) were 0.076 (0.053–0.104) in nsSag and 0.082 (0.055–0.118) in nsMet, compared with 0.062 (0.042–0.089) in non‐transmitted parental alleles and 0.065 (0.063–0.067) in gnomAD v.4.0.0 non‐Finnish European control genomes. In summary, we observed a non‐significant excess, compared to gnomAD data, of 11A alleles in both nsSag (relative risk 1.18, 95% CI 0.83–1.67) and nsMet (relative risk 1.29, 95% CI 0.87–1.92), but we did not replicate the much higher excess of RUNX2 11A alleles in nsSag previously reported (p = 0.0001).
Funder
Clarendon Fund
VTCT Foundation
Somerville College, University of Oxford
NIHR Oxford Biomedical Research Centre
Radcliffe Department of Medicine, University of Oxford
Medical Research Council
Wellcome Trust